Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Cash & Equivalents data on file, last reported at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 6.56% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (down 6.56% YoY), and the FY2025 full-year result was $16.9 million, down 25.29% from the prior year.
• Cash & Equivalents retreated to $12.8 million in Q1 2026, from $16.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $287.3 million in Q1 2022 to a low of $12.8 million in Q1 2026.
• A 5-year average of $46.3 million and a median of $27.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 91.12% in 2022 and soared 68.03% in 2024, its largest moves.
• Tracing DSGN's Cash & Equivalents over 5 years: stood at $26.5 million in 2022, then fell by 20.0% to $21.2 million in 2023, then advanced by 6.43% to $22.6 million in 2024, then fell by 25.29% to $16.9 million in 2025, then fell by 24.24% to $12.8 million in 2026.
• Business Quant data shows DSGN's Cash & Equivalents at $12.8 million in Q1 2026, $16.9 million in Q4 2025, and $15.1 million in Q3 2025.